batimastat (BB 94)

structure given in first source; a synthetic matrix metalloproteinase inhibitor

Also Known As:

BB 94; (4-(N-hydroxyamino)-2-isobutyl-3-(thiophen-2-ylthiomethyl)succinyl)phenylalanine-N-methylamide; BB-94; BB94 cpd; Butanediamide, N4-hydroxy-N1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2R-(1(S*),2R*,3S*))-

Networked: 136 relevant articles (10 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gutiérrez, José María: 5 articles (06/2017 - 04/2002)
2.	Rucavado, Alexandra: 5 articles (06/2017 - 04/2002)
3.	Escalante, Teresa: 3 articles (10/2008 - 04/2002)
4.	Braccini, Tiziana: 2 articles (07/2020 - 12/2014)
5.	Grandgirard, Denis: 2 articles (07/2020 - 12/2014)
6.	Koedel, Uwe: 2 articles (07/2020 - 12/2014)
7.	Leib, Stephen L: 2 articles (07/2020 - 12/2014)
8.	Oggioni, Marco R: 2 articles (07/2020 - 12/2014)
9.	Ricci, Susanna: 2 articles (07/2020 - 12/2014)
10.	Cayabyab, Francisco S: 2 articles (09/2017 - 07/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2020 - "BB-94 combined with RFA reduced the invasiveness of the liver tumor and improved the end-point survival. " 01/01/2014 - "The in vivo studies demonstrated that batimastat could suppress the growth of the subcutaneous tumors formed by the SCLs. " 01/01/1999 - "The purpose of this study was to determine MMP-2 and MMP-9 activity in orthotopic tumors from mice treated with and without BB-94. " 01/01/2020 - "First, 32 mice with one tumor were randomized into four groups (n = 8 each group): control (PBS only), RFA alone (65°C, 5 min), BB-94 (30 mg/kg), RFA+BB-94. " 10/18/2013 - "Moreover, treatment of batimastat-treated cells with recombinant sAPPα reversed the inhibitory effect of the drug thereby indicating that sAPPα can indeed induce proliferation of cancer cells. "
2.	Wounds and Injuries (Trauma) 12/15/2015 - "Protective effects of batimastat against hemorrhagic injuries in delayed jellyfish envenomation syndrome models." 05/22/2019 - "Active MMP-8 and MMP-9 were observed in mouse and human diabetic wounds using a batimastat affinity resin and proteomics. " 03/01/2010 - "BB-94 delayed wound contraction, as well as all other associated aspects of wound healing examined, including myofibroblast formation, stromal cell proliferation, blood vessel formation, and epithelial wound coverage. " 09/01/2002 - "BB-94 strongly enhanced wound strength, but only on day 3, when it was at its lowest. " 12/15/2015 - "Although it may require further clinical studies in the near future, the current study opens up the possibilities for the use of the metalloproteinase inhibitor, BB-94, in the treatment of multiple organ hemorrhagic injuries in DJES. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 05/01/1997 - "In vivo, using an established orthotopic model for pancreatic cancer (LD100 = 80 days), 22 nude mice with orthotopic tumors (30 were implanted) received either BB-94 or vehicle beginning 4 days prior to implantation and continuing to death or sacrifice on Day 70. " 06/15/1999 - "The previously described salutary effects of MMP blockade in mice implanted with pancreatic cancer can be explained in vitro by a dose-dependent diminution of MMP-2 activity and activation in PANC cells exposed to BB-94." 06/15/1999 - "The poorly differentiated pancreatic cancer cell line PANC-1 was stimulated in vitro with the phorbol ester PMA (20 nM) and grown in the presence of increasing doses of BB-94 (0, 40, 200, and 400 ng/ml) for 24 h. " 06/15/1999 - "We have shown previously that the metalloproteinase inhibitor, BB-94, prolongs survival and attenuates MMP-2 activity in a murine model of pancreatic cancer. " 06/15/2000 - "The purpose of this study was to determine whether BB-94 was better than cytotoxic therapy and would increase the efficacy of cytotoxic therapy (gemcitabine) in a murine model of human pancreatic cancer. "
4.	Hemorrhage 12/31/2014 - "Mice that received BB-94 presented significantly diminished MMP-9 levels (p < 0.01), intracerebral bleeding (p < 0.01), and blood-brain barrier (BBB) breakdown (p < 0.05) in comparison with untreated animals. " 03/01/2002 - "Rats treated with BB-94 and tPA showed significantly reduced hemorrhage volumes compared with those that received tPA alone. " 12/01/2000 - "However, when the combination of BB-94 and tPA was administered to rabbits, there was only a 41% incidence of hemorrhage (compared with 77% in the tPA group; P:<0. " 12/01/2000 - "The rabbits treated with BB-94 had an 18% incidence of hemorrhage (P:>0.05 compared with control). " 06/15/2017 - "by administering the inhibitor after envenoming, Batimastat completely abrogated local hemorrhage if injected immediately after venom. "
5.	Necrosis 02/01/2003 - "Animals in the BB-94 group had decreased amylase levels (1086.0 +/- 61.7 U/L vs 2232.7 +/- 309.9 U/L; P < 0.05), decreased cellular infiltrate (1.4 +/- 0.2 vs 2.3 +/- 0.2; P < 0.02), and decreased necrosis (4.1 +/- 0.3 vs 6.1 +/- 0.4; P < 0.005) compared to the control group. " 12/15/2015 - "In addition, being consistent with the imaging results, histopathological and terminal deoxynucleotidyl transferase-mediated UTP end labeling (TUNEL)-like staining observations also clearly corroborated this hypothesis, as BB-94 was highly effective in neutralizing TE-induced extensive hemorrhage and necrosis in DJES rat model. " 07/01/2010 - "Chronic administration of batimastat (BB-94), a broad spectrum peptide inhibitor of MMPs, reduced necrosis, infiltration of macrophages, centronucleated fibers, and the expression of embryonic myosin heavy chain in skeletal muscle of mdx mice. " 11/01/2001 - "In a mouse model of lethal hepatitis induced by TNF, apoptosis and necrosis of hepatocytes, but also lethality, hypothermia and influx of leukocytes into the liver, are prevented by a broad-spectrum matrix metalloproteinase (MMP) inhibitor, BB-94. " 03/01/2004 - "Hmeprin is inhibited by hydroxamic acid derivatives such as batimastat, galardin and Pro-Leu-Gly-hydroxamate, by TAPI-0 (tumour necrosis factor alpha protease inhibitor-0) and TAPI-2, and by thiol-based compounds such as captopril. "

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)
2.	Metalloproteases (Metalloproteinases)
3.	batimastat (BB 94)
4.	Doxycycline (Periostat)
5.	Gemcitabine
6.	Enzymes
7.	Gelatinases
8.	Caseins (Casein)
9.	Uridine Triphosphate (UTP)
10.	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)

Related Therapies and Procedures

1.	Therapeutics
2.	Laminectomy
3.	Radiofrequency Ablation
4.	Ligation
5.	Intraperitoneal Injections